PROCEPT BioRobotics (NASDAQ:PRCT) Issues Earnings Results

PROCEPT BioRobotics (NASDAQ:PRCT) posted its quarterly earnings results on Wednesday. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.21), FiscalAI reports. PROCEPT BioRobotics had a negative return on equity of 24.82% and a negative net margin of 31.02%.The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. During the same quarter last year, the firm earned ($0.35) EPS. The business’s revenue was up 11.9% on a year-over-year basis.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• Q4 saw approximately 12,200 U.S. procedures (≈69% YoY) and an installed base of 718 systems (≈42% YoY), with Q4 revenue of $76.4M — indicating strong procedure adoption and system placements.
• Management eliminated end‑of‑quarter bulk handpiece discounts, which drove Q4 handpiece sales down to ~80% of procedures and caused a near‑term revenue shortfall that reduced projected 2026 handpiece revenue.
• The pricing change improved handpiece economics — ASP rose to $3,340 in Q4 and management now models an ASP of $3,500 for 2026, which they say meaningfully offsets the unit‑volume revenue impact and supports margins.
• PROCEPT reorganized commercial operations into integrated regional teams and created a dedicated launch team to standardize and accelerate system activations; a pilot cut time to the first 10 cases by ~50%, though the changes caused short‑term field disruption.
• 2026 guidance was reset to $390M–$410M revenue (27%–33% growth) with US procedures 60k–64k; management forecasts ~65% gross margin, ~$350M OpEx, an Adjusted EBITDA loss of $30M–$17M, and expects positive EBITDA in Q4 2026, with $285M cash on hand.

PROCEPT BioRobotics Stock Down 1.8%

PRCT traded down $0.43 on Friday, reaching $23.20. The company’s stock had a trading volume of 292,789 shares, compared to its average volume of 1,395,127. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -13.68 and a beta of 0.99. PROCEPT BioRobotics has a fifty-two week low of $19.35 and a fifty-two week high of $66.85. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average of $30.18 and a two-hundred day moving average of $33.64.

Key Stories Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Management set 2026 revenue guidance of $390M–$410M, which is slightly above the consensus estimate (~$384M) and was highlighted at Investor Day as a multi‑year growth target. Article Title
• Positive Sentiment: Q4 showed revenue growth (+11.9% YoY) and improved operating/net losses versus prior year; cash and cash equivalents remained healthy (~$286.5M at quarter end), giving the company runway to execute its plan. Article Title
• Neutral Sentiment: The company hosted a 2026 Investor Day and published slides outlining strategy, market opportunity and the multi‑year outlook — useful for longer‑term investors but did not fully counter near‑term earnings concerns. Article Title
• Neutral Sentiment: Investor Day slides and the earnings‑call transcript were posted (useful for modeling and management commentary). Investor Day Slideshow Earnings Call Transcript
• Negative Sentiment: Q4 EPS missed badly: loss of $0.53 vs. consensus loss ~$0.32; revenue $76.4M missed estimates (~$93–96M). The shortfall and margin pressures drove immediate negative sentiment. Press Release
• Negative Sentiment: Near‑term revenue guidance (Q1 2026) was weak: $79M–$82M vs. consensus ~$93.7M — this sizable shortfall is a primary driver of today’s selloff. Press Release
• Negative Sentiment: Multiple sell‑side firms cut targets and/or ratings this week (Bank of America to Underperform/$20, Leerink to $30, Piper Sandler to $28, TD Cowen trimmed target to $34, Jefferies downgraded to Hold), increasing downside pressure and lowering analyst support. Analyst Coverage Jefferies Downgrade TD Cowen
• Negative Sentiment: A law firm (Ademi LLP) announced an investigation into possible securities‑fraud claims related to the company’s statements — a legal cloud that can further depress sentiment until resolved. PR Newswire
• Negative Sentiment: Market commentary flagged the stock hitting a 52‑week low after the results and guidance, amplifying the negative momentum. Benzinga

Analysts Set New Price Targets

Several research analysts recently commented on PRCT shares. Jefferies Financial Group cut PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Wells Fargo & Company decreased their price objective on PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating for the company in a research note on Thursday. TD Cowen cut their target price on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a research note on Thursday. Oppenheimer reiterated a “market perform” rating on shares of PROCEPT BioRobotics in a research note on Thursday. Finally, Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a report on Tuesday, December 2nd. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $43.60.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC lifted its holdings in shares of PROCEPT BioRobotics by 709.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,266 shares of the company’s stock valued at $361,000 after purchasing an additional 5,492 shares during the last quarter. Brevan Howard Capital Management LP purchased a new position in PROCEPT BioRobotics during the 2nd quarter worth approximately $407,000. Prudential Financial Inc. increased its position in PROCEPT BioRobotics by 100.4% during the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock worth $393,000 after buying an additional 3,415 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in PROCEPT BioRobotics in the third quarter valued at approximately $227,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of PROCEPT BioRobotics by 63.1% in the fourth quarter. Russell Investments Group Ltd. now owns 7,113 shares of the company’s stock valued at $224,000 after acquiring an additional 2,753 shares during the period. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.